Maximizing value: The role of axicabtagene ciloleucel in the management of large B-cell lymphoma

Chimeric antigen receptor (CAR) T-cell therapies represent a new frontier in the treatment of relapsed or refractory (R/R) large B-cell lymphoma (LBCL). This innovative immunotherapy harnesses the power of the patient’s own immune cells to target and eliminate cancer cells, resulting in remarkable improvements of 23–59% in overall survival (OS) rates at 12 months and improvements of 40–54% in complete response (CR) rates, as demonstrated in patients with diffuse LBCL (DLBCL).^1-3